EP3220954A4 - Verfahren zur herstellung einer parenteralen formulierung von anidulafungin - Google Patents

Verfahren zur herstellung einer parenteralen formulierung von anidulafungin Download PDF

Info

Publication number
EP3220954A4
EP3220954A4 EP15861353.9A EP15861353A EP3220954A4 EP 3220954 A4 EP3220954 A4 EP 3220954A4 EP 15861353 A EP15861353 A EP 15861353A EP 3220954 A4 EP3220954 A4 EP 3220954A4
Authority
EP
European Patent Office
Prior art keywords
anidulafungin
preparation
parenteral formulation
parenteral
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15861353.9A
Other languages
English (en)
French (fr)
Other versions
EP3220954A2 (de
Inventor
Mitesh Natavarlal Patel
Mafatlal Tribhovandas DAVE
Pranavkumar Jayesh Choksi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gufic Biosciences Ltd
Original Assignee
Gufic Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gufic Biosciences Ltd filed Critical Gufic Biosciences Ltd
Publication of EP3220954A2 publication Critical patent/EP3220954A2/de
Publication of EP3220954A4 publication Critical patent/EP3220954A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP15861353.9A 2014-11-19 2015-09-07 Verfahren zur herstellung einer parenteralen formulierung von anidulafungin Withdrawn EP3220954A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3668MU2014 2014-11-19
PCT/IN2015/000349 WO2016079749A2 (en) 2014-11-19 2015-09-07 Process for preparation of parenteral formulation of anidulafungin

Publications (2)

Publication Number Publication Date
EP3220954A2 EP3220954A2 (de) 2017-09-27
EP3220954A4 true EP3220954A4 (de) 2018-06-27

Family

ID=56014644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15861353.9A Withdrawn EP3220954A4 (de) 2014-11-19 2015-09-07 Verfahren zur herstellung einer parenteralen formulierung von anidulafungin

Country Status (4)

Country Link
EP (1) EP3220954A4 (de)
EA (1) EA201791100A1 (de)
WO (1) WO2016079749A2 (de)
ZA (1) ZA201703330B (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105767A2 (en) * 2002-06-13 2003-12-24 Vicuron Pharmaceuticals, Inc. Antifungal parenteral products
US6960564B2 (en) * 1999-03-03 2005-11-01 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
CN107049935A (zh) * 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960564B2 (en) * 1999-03-03 2005-11-01 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
WO2003105767A2 (en) * 2002-06-13 2003-12-24 Vicuron Pharmaceuticals, Inc. Antifungal parenteral products

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AÏCHA GHARBI ET AL: "Elaboration of antibiofilm surfaces functionalized with antifungal-cyclodextrin inclusion complexes", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY., vol. 65, no. 2, 1 July 2012 (2012-07-01), NL, pages 257 - 269, XP055475652, ISSN: 0928-8244, DOI: 10.1111/j.1574-695X.2012.00932.x *

Also Published As

Publication number Publication date
WO2016079749A3 (en) 2016-07-21
WO2016079749A2 (en) 2016-05-26
EA201791100A1 (ru) 2017-11-30
ZA201703330B (en) 2019-07-31
EP3220954A2 (de) 2017-09-27

Similar Documents

Publication Publication Date Title
EP3204433B8 (de) Verfahren zur herstellung von alpha-nukleiertem polypropylen
EP3215655A4 (de) Verfahren zur herstellung von gleitbeschichtungen
EP3325443A4 (de) Verfahren zur herstellung von pridopidin
IL254894B (en) A process for the preparation of dicycloplatin
EP3166931A4 (de) Verbessertes verfahren zur herstellung von exametazim
EP3230280A4 (de) Verfahren zur herstellung von luliconazol
EP3196196A4 (de) Verfahren zur herstellung von calcobutrol
EP3148979A4 (de) Verfahren zur herstellung von canagliflozin
EP3341359A4 (de) Verfahren zur herstellung von apremilast
EP3134415A4 (de) Verbessertes verfahren zur herstellung von rifamyciderivaten
EP3237424A4 (de) Verfahren zur herstellung von cenicriviroc und zugehörigen analoga
EP3149011A4 (de) Verfahren zur synthetisierung von diisopropylaminw-disilanen
EP3148540A4 (de) Verfahren zur herstellung von cyclischen depsipeptiden
EP3107542A4 (de) Verfahren zur herstellung von n-benzyl-3-hydroxy-4-substituierten-pyridin-2-(1h)-onen
IL248267A0 (en) A process for preparing converted cycloserines
EP3265100A4 (de) Verfahren zur herstellung von fluorketoliden
EP3173380A4 (de) Trichlorsilanherstellungsverfahren
EP3227246B8 (de) Oxy-calcinationsverfahren
EP3177610A4 (de) Verfahren zur herstellung polymorpher formen von nilotinib
EP3201171A4 (de) Verfahren zur herstellung eines zwischenprodukts von salmeterol
EP3386944A4 (de) Verfahren zur herstellung von lisdexamphetamin
EP3174878A4 (de) Verfahren zur herstellung von palbociclib
EP3154951A4 (de) Verfahren zur herstellung eines chinazolinderivats
EP3140308B8 (de) Verfahren zur herstellung von opioidverbindungen
EP3201215A4 (de) Verfahren zur herstellung eines zwischenprodukts von fluticasonpropionat

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180530

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/19 20060101ALI20180524BHEP

Ipc: A61K 38/12 20060101AFI20180524BHEP

Ipc: A61K 47/40 20060101ALI20180524BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190828